The University of California, San Francisco is the lead institution on a new seven-year, $17 million multicenter study funded by the National Institutes of Health to determine if certain immune system cells and/or a drug now used for treating rheumatoid arthritis can be effective in improving and maintaining the long-term health of kidney transplant recipients.
The goal of this study is to reduce or eliminate inflammation in kidney transplants and prevent the associated decline in function, thereby maximizing long-term organ survival. It will involve two clinical trials and research in parallel by biologists and by researchers for the mechanistic cores.
The principal investigator of the study is Flavio Vincenti, MD, UCSF professor of medicine and a kidney and pancreas transplant specialist at UCSF Medical Center. Other participating institutions are the University of Alabama at Birmingham, Emory University, and Cedars-Sinai Medical Center.
Despite advances in transplantation—reducing early acute rejection rates to less than 15% and improving one-year graft survival to more than 90%—long-term graft success rates have remained unchanged at 4% loss annually. A major contributor is progression of interstitial fibrosis and tubular atrophy in the kidney.
The cells that the researchers are focused on are regulatory T cells (Tregs), which are a small population of lymphocytes that suppress the activity of other immune cells, according to UCSF. They maintain normal immune system homeostasis and safeguard against autoimmune diseases, and their immunosuppressive properties also can be harnessed to control transplant rejection. The trials will also focus on the use of an anti-IL6 receptor antibody.
Tregs have the potential to induce long-term donor-specific tolerance without impeding desired immune responses to pathogens and tumors in transplant patients.
Sixty-five patients are enrolled in all three sites. The trials are expected to begin in the fall.